Skip to main content
BDX logo
BDX
(NYSE)
Becton, Dickinson and Company
$152.97-- (--)
Loading... - Market loading

Becton, Dickinson and Company (BDX) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Becton, Dickinson and Company
BDXNew York Stock ExchangeHealthcareMedical Instruments & Supplies

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Stock Details

ExchangeNew York Stock Exchange (NYSE)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.bd.com
Phone201 847 6800
Address
1 Becton Drive Franklin Lakes, New Jersey 07417-1880 United States

Corporate Identifiers

CIK0000010795
CUSIP075887109
ISINUS0758871091
EIN22-0760120
SIC3841

Leadership Team & Key Executives

Thomas E. Polen Jr.
President, Chief Executive Officer and Chairman
Michael Garrison
Executive Vice President and President of Medical Segment and BioPharma Systems Segments
Michael C. Feld
Executive Vice President and Chief Revenue Officer
Vitor Roque
Executive Vice President and Chief Financial Officer
Elizabeth McCombs
Executive Vice President and Chief Technology Officer
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.
Senior Vice President and Chief Scientific Officer
Denise Russell Fleming
Executive Vice President and Chief Information Officer
Lanesha T. Minnix J.D.
Executive Vice President and General Counsel
Carla Burigatto
Senior Vice President and Chief Communications Officer
Meera Gopalakrishnan
Senior Vice President and Global Chief Marketing Officer